Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Female patients with confirmed HER-2 positive , non-operable locally advanced or metastatic breast cancer
All patients must have received at least 1 but no more than 2 prior anti HER2 based regimens including at least 1 regimen containing Trastuzumab.
All patients must have at least one measurable lesion as defined by RECIST criteria.
All patients must have documented progressive disease following the last line of therapy before entering the study
ECOG Performance status ≤ 1
You may not be if
Patients with known CNS metastasis which are: symptomatic or require treatment for symptom control and/or growing
Prior treatment with any HSP90 or HDAC inhibitor
Impaired cardiac function
Acute or chronic liver or renal disease
Patients who are currently receiving treatment with any medication which has a relative risk of prolonging the QTc interval or inducing Torsades de Pointes and cannot be switched or discontinued to an alternative drug prior to commencing AUY922
Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
Patients who do not have either an archival tumor sample available or are unwilling to have a fresh tumor sample collected at baseline.
